Can Korlym Drive Corcept's Growth Through the Rest of 2025?

Corcept Therapeutics reported H1 2025 Korlym sales of $351.6 million, up 13.2% year-over-year, with management forecasting stronger H2 growth to achieve full-year revenues of $850-$900 million as vendor issues ease. The company's future growth is heavily reliant on relacorilant, its lead pipeline candidate for Cushing's syndrome, which has an FDA decision target date of December 30, 2025, and is anticipated to replace Korlym while expanding market access. Despite a 38.3% YTD stock rally, CORT trades at a significant valuation premium, and recent analyst consensus estimates for 2025 and 2026 EPS have been downgraded, resulting in a Zacks Rank #4 (Sell).

Analysis

Corcept Therapeutics (CORT) presents a mixed investment profile, balancing strong current performance against significant forward-looking risks and a high valuation. The company's sole revenue source, Korlym, demonstrated robust growth with a 13.2% year-over-year increase in sales to $351.6 million for the first half of 2025, and management anticipates further acceleration in the second half to meet its full-year revenue guidance of $850-$900 million as earlier pharmacy vendor issues are resolved. However, the company's future is fundamentally dependent on the FDA's decision regarding its lead pipeline candidate, relacorilant, for Cushing's syndrome, with a pivotal PDUFA target date of December 30, 2025. While a potential approval is expected to drive growth by replacing Korlym and expanding into new indications like ovarian cancer, the stock's significant year-to-date rally of 38.3% has pushed its valuation to a substantial premium, trading at a price-to-sales ratio of 11.73 versus the industry average of 2.38. This optimistic market pricing is directly at odds with recent analyst sentiment, as consensus EPS estimates for both 2025 and 2026 have been revised downward over the past 60 days, contributing to its Zacks Rank #4 (Sell).

Key Decisions for Investors

• Investors should view Corcept as a high-risk, event-driven holding, as its valuation is heavily predicated on the FDA's approval of relacorilant by the critical December 30, 2025 PDUFA date.
• The significant disconnect between the stock's premium valuation and the recent downward revisions of 2025 and 2026 consensus EPS estimates warrants considerable caution, suggesting current prices may not reflect underlying earnings risk.
• Monitor upcoming quarterly reports to confirm that Korlym sales accelerate as guided, as any shortfall against the $850-$900 million full-year revenue target would signal operational weakness and could significantly increase pressure on the stock ahead of the binary FDA decision.